Navigation Links
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
Date:4/14/2008

de extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

Cephalon Europe

Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four therapeutic areas: central nervous system, pain, primary care and oncology.

Among its oncology products, Cephalon Europe markets MYOCET(R) (liposomal doxorubicin) which is indicated in combination with cyclophospamide for first- line treatment of metastatic breast cancer; TARGRETIN(R) (bexarotene) for advanced cutaneous T-cell lymphoma; and TRISENOX for relapsed or refractory acute promyelocytic leukemia.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products, including with respect to EFFENTORA; sales, adjusted net income and basic adjusted income per common share guidance;
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
3. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
4. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
5. Cephalon General Counsel John E. Osborn to Resign Position
6. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
7. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
8. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
9. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
10. Cephalon Submits Supplemental New Drug Application for FENTORA
11. Cephalon Announces Strong Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Cord Blood Corporation (NYSE: CO ) ("CCBC," the "Company," ... provider of cord blood collection, laboratory testing, hematopoietic stem cell ... Special Committee of the Company,s board of directors (the "Special ... ) Limited as its independent financial advisor, Cleary ... United States legal counsel and Maples & Calder ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 German-based Moenninghoff ... United States distributor for the Moenninghoff product line ... “I am pleased to announce that the R.M. Hoffman ... For our firm, founded in 1916, this is a ... Hoffman is the kind of professional distributor we need ...
(Date:6/1/2015)... South Korea , June 1, 2015 ... Inc. (GCBT) kicked off construction today on its biopharmaceutical ... Saint-Laurent Campus. The CA$315 million project represents one of ... Canada in the biopharmaceutical industry, giving place ... and albumin manufacturing plant in Canada ...
(Date:6/1/2015)... HANOVER, N.J. , June 1, 2015 /PRNewswire/ ... II clinical study of CTL019, an investigational chimeric ... its potential in the treatment of specific types ... study conducted by the University of Pennsylvania,s Perelman ... or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) ...
Breaking Biology Technology:China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... , BIRMINGHAM, Ala. , Jan. 19 ... when it comes to cholesterol. According to a new study, a ... — can be labeled "bad cholesterol." The landmark study Genetic ... published in the New England Journal Of Medicine provides ...
... , , NEW HAVEN, Conn. , ... today that it has appointed Dr. Richard J. Carroll ... Research. , Dr. Carroll brings to HistoRx over 20 years ... diagnostic, pharmaceutical and medical device industries. Before joining HistoRx in ...
... CITY, China , Jan. 19 /PRNewswire-Asia-FirstCall/ -- ... fully,integrated and highly innovative biopharmaceutical company engaged in the,research and ... today announced financial results for the second quarter ended, November ... 2010 Highlights, -- Total revenue increased by ...
Cached Biology Technology:New Study: Lp(a) Joins LDL as Heart Disease Risk Factor 2New Study: Lp(a) Joins LDL as Heart Disease Risk Factor 3HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 2HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 3Sinobiopharma Announces Second Quarter 2010 Financial Results 2Sinobiopharma Announces Second Quarter 2010 Financial Results 3Sinobiopharma Announces Second Quarter 2010 Financial Results 4
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
(Date:4/27/2015)... 2015  For more than four decades, AUVSI,s ... the premier worldwide event for the unmanned land, sea, ... event for any local, national, or trade news organization ... markets and current applications of unmanned technologies. The conference ... $48 billion industry, and how it will soon impact ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... 18, 2009 Pharmaceuticals and personal care products (PPCPs) ... reach surface waters or groundwater when these materials ... the high flow conditions created by land application ... of solutes in soil macropores may be too ...
... radiation therapy treatment damages a patient,s healthy tissue as ... destroy, making the treatment especially invasive and often causing ... will enable a far more precise and accurate treatment ... the radiation beam. Real-time image-guided radiotherapy, combining radiation ...
... available in French . , Montreal, May ... known to humans, and its abuse has become widespread since ... we know rather little about its effects on the human ... latest article by Dr. Marco Leyton, of the Montreal Neurological ...
Cached Biology News:Simulating pharmaceutical and personal care product transport 2Cocaine: Perceived as a reward by the brain? 2
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
...
Antibody Diluent for IHC 125 ml...
Biology Products: